Thursday, July 16, 2009

Views on the exclusivity period of biogenerics

Bio and GPhA have released statements about the twelve year exclusivity period that was amended by the Senate Committee on Health, Education, Labor, and Pensions (HELP) for biologics last week.

Bio stated “the HELP Committee has embraced our long held belief that a minimum of 12 years of data exclusivity establishes a fair and reasonable period to ensure continued biomedical innovation and provide the benefits of expanded competition.”

GPhA President and CEO Kathleen Jaeger claimed that her company would “continue to fight in the House to ensure a true balance is achieved between innovation and competition.”

For a more in-depth look at the reactions, read here.

If you're interested in networking with other professionals in the field of Biosimilars, join our LinkedIn Group here.


Share this article with your social network, just click below to share now!


1 comment :

Evan said...

AS with publishing, any targets discovered with the assistance of federal grants should have fewer years than those targets and products discovered without federal aid.

Post a Comment